A Randomized, Double-Blind, Placebo-Controlled, 4-Treatment, 3-Period, Incomplete Block, Balanced Crossover Study to Evaluate the Effects of a Single Dose of Aliskiren and Losartan on Renal Blood Flow Measurements in Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 06 Apr 2010
At a glance
- Drugs Aliskiren; Losartan
- Indications Hypertension
- Focus Pharmacodynamics
- Sponsors Merck & Co
- 06 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 25 Feb 2010 Planned end date changed from 1 Mar 2010 to 1 Apr 2010 as reported by ClinicalTrials.gov.